BMY icon

Bristol-Myers Squibb
BMY

Upgrade to unlock
Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 31.6%
Negative

Positive
The Motley Fool
5 hours ago
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement
Bristol Myers Squibb is operating in the shadow of the hype surrounding GLP-1 drugs. The company has an attractive and well-supported yield.
Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement
Neutral
Zacks Investment Research
yesterday
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.37, marking a +2.08% move from the previous day.
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Positive
Zacks Investment Research
2 days ago
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
Positive
24/7 Wall Street
2 days ago
Retirees Are Quickly Moving Into These Dividend Funds
Shifting from higher-risk assets to consistent income sources is a natural progression for retirees.
Retirees Are Quickly Moving Into These Dividend Funds
Neutral
Business Wire
2 days ago
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable.
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Positive
Zacks Investment Research
3 days ago
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Positive
24/7 Wall Street
3 days ago
5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever
While many Baby Boomers have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.
5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever
Neutral
PRNewsWire
3 days ago
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 25, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.
NYSE Content Update: Two MSCI Indexes to Begin Trading on NYSE Arca Options
Positive
Zacks Investment Research
4 days ago
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Neutral
Business Wire
5 days ago
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference.
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
See News Rankings